Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
A method is provided in various embodiments for determining a profile data set for a subject with rheumatoid arthritis or inflammatory conditions related to rheumatoid arthritis based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 2 constituents from Tables 1-2 and Tables 4-10. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.
1. A method of determining whether a human subject is suffering from or is at risk of developing rheumatoid arthritis, based on a blood sample from the subject, the sample providing a source of RNAs, the method comprising:
using quantitative amplification to obtain a quantitative measure of the amount of at least 2 constituents as distinct RNA constituents in the subject sample, wherein the first constituent is selected from the group consisting of TLR2, MMP9 and TGFB1, and the second constituent is selected from the group consisting of CD4, PTGS2 and HSPA1A, wherein the constituents are selected so as to distinguish from a normal and a rheumatoid arthritis-diagnosed subject with at least 75% accuracy, and wherein such measure for each constituent is obtained under measurement conditions that are (i) within a degree of repeatability of better than five percent; and (ii) the efficiencies of amplification are within two percent for each constituent, to arrive at a subject profile data set of a plurality of members;
assessing the subject profile data set; and
comparing the subject profile data set to a baseline profile data set, wherein the baseline profile data set is derived from one or more subjects known not to be suffering from rheumatoid arthritis;
wherein a change in the expression pattern of the subject profile data set as compared to the baseline profile data set indicates that the subject is suffering from or is at risk of developing rheumatoid arthritis.
2. The method of claim 1 , wherein said rheumatoid arthritis-diagnosed subject is washed out from therapy.
3. A method of claim 1 , wherein the constituents are selected as to permit characterizing the severity of rheumatoid arthritis in relation to a normal subject over time so as to track movement toward normal as a result of successful therapy and away from normal in response to symptomatic flare.
4. The method of claim 1 , wherein the at least the first constituent includes TRL2.
5. A method according to claim 1 , further comprising obtaining quantitative measure of one or more constituents selected from the group consisting of IL18BP, HMBG1, C1QA, SERPING1, MYC, NFKB1, TNFSF5, LTA, TGFB1, DPP4, EGR1, IL1R1, ICAM1, IL1RN, TIMP1, MPO, MMP9, TNFSF6, IL1B, IFI16, and SERPINE1.
6. The method of claim 1 , wherein the at least the first constituent includes MMP9.
7. A method according to claim 1 , further comprising obtaining quantitative measure of one or more constituents selected from the group consisting of PTGS2, IFI16, C1QA, IL1R1, MYC, SERPINE1, MPO, NFKB1, TGFB1, EGR1, PLAUR, TNFSF5, SERPINA1, LTA, TIMP1, ICAM1, TNF, TLR2, and IL1B.
8. The method of claim 1 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than three percent.
9. The method of claim 1 , wherein the efficiency of amplification for all constituents is less than one percent.